aTyr Pharma

aTyr Pharma is a biopharmaceutical company that discovers and develops protein biologics for human therapeutics. The company has established a significant intellectual property portfolio around physiocrine-based compositions and their potential therapeutic applications. aTyr’s lead programs are focused on immunological disorders in the inflammation and immunology space, currently in preclinical development. The company’s primary focus is ATYR1923, a clinical-stage product candidate that binds to the neuropilin-2 receptor and is designed to modulate the immune response in patients with interstitial lung disease.